Excellent Oral Presentation: “Optimization of Canine Platelet-Rich Plasma Concentration for Anti-inflammatory Activity and Chondrogenic Differentiation In Vitro” at the National Biotechnology Conference 2026

On August 7-8, 2026, the National Biotechnology Conference 2026 was held at Dong A University (Da Nang City, Vietnam), hosted by Dong A University.

The National Biotechnology Conference is an annual scientific forum aimed at strengthening connections and sharing knowledge and research findings among scientists, experts, lecturers, and researchers from universities, research institutes, enterprises, and domestic and international science and technology organizations across various biotechnology-related fields. The conference featured 04 plenary presentations and 183 oral and poster presentations across 07 specialized subcommittees: Genetic Technology; Cell Technology; Biochemistry & Protein Technology; Agricultural Biotechnology; Microbial, Food and Environmental Biotechnology; Medical Biotechnology and AI Applications; and Regenerative Medicine and Cell Therapy.

At this conference, the Biotechnology Center of Ho Chi Minh City received 01 Excellent Oral Presentation Award in the Regenerative Medicine and Cell Therapy subcommittee for the presentation “Optimization of Canine Platelet-Rich Plasma Concentration for Anti-inflammatory Activity and Chondrogenic Differentiation In Vitro,” presented by Dr. Truong Minh Dung’s team from the Division of Biomaterial and Nano Technology, Biotechnology Center of Ho Chi Minh City. Platelet-rich plasma (PRP) is a promising autologous biological product enriched with growth factors that regulate inflammation and promote tissue regeneration. However, the optimal PRP concentration for cartilage regeneration remains unclear. This study aimed to characterize canine PRP and determine its optimal concentration by evaluating biocompatibility, anti-inflammatory activity, and chondrogenic differentiation in vitro. PRP was prepared from the peripheral blood of juvenile dogs using a two-step centrifugation protocol. Platelet concentration and the release kinetics of platelet-derived growth factor-AB (PDGF-AB) and transforming growth factor-β1 (TGF-β1) were determined. Biocompatibility was evaluated in canine bone marrow-derived mesenchymal stem cells (BMSCs) using the WST-1 assay. Anti-inflammatory activity was assessed in lipopolysaccharide (LPS)-stimulated RAW 264.7 macrophages by measuring nitric oxide (NO) production. Chondrogenic differentiation was further examined using Safranin O staining and glycosaminoglycan (GAG) quantification. PRP contained a mean platelet concentration of 1,662 × 10⁶/mm³. PDGF-AB exhibited rapid release during the first hour after activation, whereas TGF-β1 remained relatively stable over 72 h. PRP concentrations ranging from 6.25% to 50% showed no cytotoxicity toward BMSCs, with 12.5% yielding the highest cell viability (114.03 ± 3.81%). Notably, 12.5% PRP also demonstrated the strongest anti-inflammatory activity, reducing NO production by 50.58%. Furthermore, treatment with 12.5% PRP markedly enhanced proteoglycan deposition and increased GAG content to 21.775 μg/mL, indicating enhanced chondrogenic differentiation. Collectively, these findings identify 12.5% PRP as the optimal concentration, providing a promising strategy for cartilage regeneration and regenerative veterinary medicine.

Fig. 1  Representatives of the author group receiving certificates for excellent oral presentations at the subcommittees.

Fig. 2 Certificate for the excellent oral presentation in the the Regenerative Medicine and Cell Therapy, Biotechnology subcommittee.